Baker Bros. Advisors Adds $21M in Aktis Oncology, Inc. ($AKTS)
Key Points
- Wall Street's consensus rating on $AKTS is Strong Buy and an average price target of $32.65.
- $AKTS last traded around $21.03.
Baker Bros. Advisors acquired a new position in Aktis Oncology, Inc. ($AKTS), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 996,351 shares of Aktis Oncology, Inc.. Baker Bros. Advisors's holdings in Aktis Oncology, Inc. were worth $20.95 million as of its most recent filing.
Aktis Oncology, Inc. ($AKTS) Stock
Aktis Oncology, Inc. Earnings
Analysts Set New Price Targets
About Aktis Oncology, Inc.
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.